323 related articles for article (PubMed ID: 28733704)
1. [Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].
Widmann G; Nguyen VA; Plaickner J; Jaschke W
Radiologe; 2017 Oct; 57(10):840-849. PubMed ID: 28733704
[TBL] [Abstract][Full Text] [Related]
2. Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.
Widmann G; Nguyen VA; Plaickner J; Jaschke W
Curr Radiol Rep; 2016; 5(11):59. PubMed ID: 28959504
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy.
Ezponda Casajús A; Calvo Imirizaldu M; de Torres Tajes JP; García-Baizán A; Castañón Álvarez E; Cano Rafart D; Vivas Pérez I; Bastarrika Alemañ G
Radiologia (Engl Ed); 2020; 62(2):131-138. PubMed ID: 31405549
[TBL] [Abstract][Full Text] [Related]
5. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Bronstein Y; Ng CS; Hwu P; Hwu WJ
AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
Lidar M; Giat E; Garelick D; Horowitz Y; Amital H; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Autoimmun Rev; 2018 Mar; 17(3):284-289. PubMed ID: 29341936
[TBL] [Abstract][Full Text] [Related]
7. Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.
Sidhu P; Menzies AM; Long G; Carlino M; Lorens S; Kapoor R
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):759-766. PubMed ID: 29024572
[TBL] [Abstract][Full Text] [Related]
8. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-induced autoimmune hypophysitis.
Valecha G; Pant M; Ibrahim U; Atallah JP
J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
[TBL] [Abstract][Full Text] [Related]
10. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
11. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
Iglesias P
Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
[TBL] [Abstract][Full Text] [Related]
13. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center.
El Majzoub I; Qdaisat A; Thein KZ; Win MA; Han MM; Jacobson K; Chaftari PS; Prejean M; Reyes-Gibby C; Yeung SJ
Ann Emerg Med; 2019 Jan; 73(1):79-87. PubMed ID: 29880440
[TBL] [Abstract][Full Text] [Related]
14. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
15. [Adverse events of immune checkpoint inhibitors].
Foller S; Oppel-Heuchel H; Fetter I; Winkler Y; Grimm MO
Urologe A; 2017 Apr; 56(4):486-491. PubMed ID: 28246759
[TBL] [Abstract][Full Text] [Related]
16. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Oral, Otologic, and Ocular Adverse Events.
Srivastava A; Al-Zubidi N; Appelbaum E; Gombos DS; Nader ME; Gidley PW; Chambers MS
Adv Exp Med Biol; 2020; 1244():295-307. PubMed ID: 32301024
[TBL] [Abstract][Full Text] [Related]
19. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Adverse Events: Pneumonitis.
Jain A; Shannon VR; Sheshadri A
Adv Exp Med Biol; 2018; 995():131-149. PubMed ID: 30539509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
